- Home
- FOXX vs ALLR Comparison
FOXX vs ALLR Comparison
Compare FOXX & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FOXX | ALLR |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9M | 16.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FOXX | ALLR |
|---|---|---|
| Price | $5.10 | $1.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | ★ 3.0M | 148.6K |
| Earning Date | 11-18-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $63,030,415.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 139.29 | N/A |
| 52 Week Low | $1.71 | $0.61 |
| 52 Week High | $11.00 | $2.35 |
Technical Indicators
Market Signals| Indicator | FOXX | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 51.79 | 37.75 |
| Support Level | $3.67 | $1.05 |
| Resistance Level | $5.38 | $1.18 |
| Average True Range (ATR) | 1.01 | 0.08 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 33.43 | 8.93 |
Price Performance
Historical ComparisonAbout FOXX Foxx Development Holdings Inc.
Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.